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MHC = major histocompatibility complex; MMP1 = matrix metalloproteinase 1; MnSOD = manganese superoxide dismutase; mtDNA = mitochondr-
ial DNA; OA = osteoarthritis; RA = rheumatoid arthritis; ROS = reactive oxygen species.
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Abstract
Somatic mutations of mitochondrial DNA have been detected in
various pathologies such as cancer, neurodegenerative diseases,
cardiac disorders and aging in general. Now it has been found that
patients with rheumatoid arthritis also have a higher incidence of
mitochondrial mutations in synoviocytes and synovial tissue
compared with patients with osteoarthritis. Furthermore, it has
been shown that these mutations possibly result in changed
peptides that are presented by major histocompatibility complex II
and thus might be recognized as non-self by the immune system.
Further studies will show whether these mutations are actually able
to trigger autoimmune inflammation in rheumatoid arthritis or
whether they must be considered epiphenomena of cellular
damage in chronic inflammation.
Rheumatoid arthritis (RA) is one of the most common
systemic autoimmune diseases. However, the pathophysio-
logical mechanisms are still not fully understood and the
etiology is simply unknown. Biomedical researchers have
investigated various aspects of this intricate disease. Da
Sylva and colleagues have now analyzed yet another piece in
the ‘RA-puzzle’. In a recent article in Arthritis Research &
Therapy, this group analyzed the presence of mitochondrial
DNA (mtDNA) mutations in patients with RA and their
possible role in the pathogenesis of RA [1]. The sequencing
of RNA transcribed from the mitochondrial MT-ND1 gene
showed a higher mutational burden (that is, changes per
base pair) in RA cultured fibroblasts and RA tissue than in
cells and tissue from patients with osteoarthritis (OA). More
importantly, in RA tissue significantly more of these mutations
resulted in non-synonymous amino acid changes than those
in tissues of patients with OA.
Mutations in mtDNA have long been thought to have a role in
the pathogenesis of various diseases. The ‘classic’ mito-
chondrial syndromes like Leigh syndrome or Leber’s hereditary
optic neuropathy are caused by inherited (germline)
mutations of mtDNA. They comprise a wide spectrum of
clinical symptoms that arise as a result of dysfunction of the
mitochondrial respiratory chain, mostly affecting tissues that
are highly dependent on oxidative metabolism such as the
nervous system or the eye [2]. In contrast, tissue-specific
accumulation of somatic (non-inherited) mtDNA mutations is
best described in various types of cancer. Somatic mtDNA
mutations have been found in breast cancer, colorectal
cancer, renal cell carcinoma, malignant glioma and
hematologic malignancies, to name only a few (reviewed in
[3]). Furthermore, it was suggested that mtDNA mutations
are involved in the development of cardiac disease [4] and
neurodegenerative disorders such as Alzheimer’s disease [5].
Finally, accumulated mtDNA mutations due to oxidative
damage are considered to be responsible for one of the basic
events of cellular life, aging itself [6].
The repeated detection of somatic mtDNA mutations in
various diseases gives rise to the old ‘chicken-and-egg’
question. Do somatic mtDNA mutations actually provoke
pathological states or should they be considered
epiphenomena? In other words, why do somatic mtDNA
mutations increase, and what consequences might they
have? As a cause of the high incidence of somatic mutations
in patients with RA, Da Sylva and colleagues suggest high
levels of reactive oxygen species (ROS) followed by selective
proliferation of synoviocytes that gained a survival advantage
through the mutation. Several groups have demonstrated a
role of ROS in RA by showing increased oxidative enzyme
activity along with decreased levels of antioxidants and by
confirming oxidative damage to hyaluronic acid, collagen and
nuclear DNA [7]. Because Da Sylva and colleagues found no
difference in the frequency of nuclear mutations (measured in
a randomly chosen nuclear gene) between patients with RA
and those with OA, they conclude that random damage, for
example by ROS, cannot be the sole cause of mtDNA
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mutations. The occurrence of nuclear mutations in RA has not
yet been fully explained. Whereas some groups describe
higher frequencies of mutations in p53 transcripts in RA than
in OA [8], others could not detect any mutated p53 at all [9].
Data on mutations in the H-ras gene in arthritic synovium
could not be verified later by the same group [10], and
mutations in WISP3 were found at similar levels in patients
with RA and in those with OA [11].
These examples suggest that the detection of nuclear
mutations might depend on the patient groups, the
inflammatory disease activity and the detection methods
used. Another possible explanation for the greater damage of
mtDNA in patients with RA might be limitations of DNA repair
in mitochondria. It is feasible that increased DNA damage
through ROS in RA can be compensated for in the nucleus
by the upregulation of repair mechanisms, whereas in the
mitochondria no such adjustment can take place. One study
that analyzed the expression of mismatch repair enzymes in
RA found upregulation of an enzyme responsible for the
repair of large insertion/deletion mispairings and down-
regulation of an enzyme mainly needed for single-base
mispairings. The authors suggest that this could be a
mechanism to shift protection from changes in single base
pairs in favor of protection from major damage to DNA [12].
In assessing the expressed mutational burden – that is,
mutations that will change mtND1 protein subunits – Da Sylva
and colleagues found it to be higher in RA tissue than in OA
tissue. This could mean that the changed protein actually contri-
butes to the activated phenotype of synoviocytes in RA [13].
MtND1 is a subunit of complex I of the respiratory chain located
at the inner mitochondrial membrane. Impairment of complex I
leads to an increased production of superoxide [14]. As a
scavenger system, manganese superoxide dismutase (MnSOD)
catalyzes the reaction of superoxide to hydrogen peroxide. Most
interestingly, MnSOD production can be stimulated by cytokines
such as tumor necrosis factor-α. The resulting hydrogen
peroxide might contribute to the elevated levels of matrix
metalloproteinase 1 (MMP1) in RA through the upregulation of
gene expression and activation of proenzymes [15].
Da Sylva and colleagues propose another mechanism for how
somatic mtDNA mutations might contribute to the
pathogenesis of RA. Using major histocompatibility complex
(MHC) epitope prediction algorithms, the authors searched for
possible epitope regions that were affected by the mutations.
They found five mutated peptides in patients with RA that
would potentially be presented by MHC II, but none in patients
with OA. Again, this difference could indicate a characteristic
feature of RA synoviocytes. The altered peptides might be
recognized as non-self after presentation and lead to the
initiation of an inflammatory response. However, neither this
hypothesis nor the complex I impairment theory can explain
how these mutational changes could possibly provide a
survival advantage for the RA synoviocytes.
Conclusion
The detection of increased somatic mtDNA mutations in RA
tissue is clearly intriguing and raises many questions that
have yet to be analyzed. One question to be solved is
whether these mutations are homoplasmic (that is, the
mutation is found in all mitochondria of a cell) or
heteroplasmic (that is, a cell can have a mixture of normal and
mutated mtDNA copies). If they are heteroplasmic, it is
questionable whether they actually affect mitochondrial
function, because the normal mtDNA copies would rescue
the cell from the loss of any mitochondrial gene product. If
mutated peptides are presented and recognized as non-self,
heteroplasmic mutations could substantially contribute to the
pathogenesis of disease, but the initial question about the
triggering factor of RA still remains unanswered. Do mtDNA
mutations initiate the autoimmune reaction in RA, or are they
a consequence of inflammatory damage to the cell? In future,
in addition to further analysis of mitochondrial mutations, it
would be worth looking at the functionality and the gene
expression pattern of mitochondria to obtain a more complete
picture of the role of mitochondria in health and disease.
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